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Abstract
This article describes the actual situation at the beginning of 1999 with regard to
identification and priority setting for health technology assessment (HTA) on a national level
in the Netherlands. For this purpose the literature on HTA published in 1980–1998, mainly
national, was thoroughly reviewed. Many policy documents and other reports from the ‘grey
literature’ of identification and priority setting for HTA in the Netherlands were also used.
The results show that attempts to identify and set priorities for HTA is a new activity in the
Netherlands. The three most important actors in the field are the Health Council, the
Council for Health Research and the Health Insurance Council. Methodologies differ
depending on the content and scope of each programme. In addition, the methods used are
not always transparent and the activities are not co-ordinated. The lack of co-ordination is
due to the fact that there is no single organisation that is authorised to identify and set
priorities for HTA. Suggestions for improving co-ordination are proposed with the aim of
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developing a truly national effort in this field, which will enable a more balanced and
efficient set of HTA activities. © 1999 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
The field of health technology assessment1 (HTA) is now almost 20 years old.
Technology assessment originally developed out of the need for information
expressed by those making important ‘technological’ decisions. In health care, this
concerns mainly the need for information on the efficacy (benefits), safety, and
financial costs of proposed new technologies. Increasingly, HTA also considers
available ‘old’ technologies and the appropriate indications for use of a technology
for different groups of patients and in different clinical settings. HTA is addition-
ally concerned with the social consequences and implications of adoption and use,
including ethical and legal concerns. Technology assessment can be defined as a
form of policy research [3,4], in the sense that information from assessments should
make a more rational and effective decision-making process possible. The central
goal is to improve the quality and cost-effectiveness of health care.
In the Netherlands, HTA was introduced around 1982 when the Health In-
surance Council (Ziekenfondsraad) was confronted with patients demanding reim-
bursement of the costs of heart and liver transplantation that had been performed
abroad. This debate stimulated a new policy, outlined in the paper ‘Limits to the
expansion of the benefit package’ of the Health Insurance Council [5]. The paper
stated that, as a prerequisite for coverage in the benefit package, both the efficacy
and the cost effectiveness of all major new health technologies should be assessed.
In addition, the Director General of Health asked the Steering Committee for
Future Health Care Scenarios (Stuurgroep Toekomstscenario’s Gezondheidszorg,
STG) for advice on a long-term policy on health technology [6]. This advice
describes the existing health policies, including policies for HTA, and reached a
number of conclusions pointing to the future. An important policy document,
partly developed in response to the STG report, was ‘Limits to care’ [7]. The
government subsequently requested advice on the question concerning establishing
a border between effective and ineffective care from three important councils: the
Health Insurance Council, the National Council for Public Health (Nationale Raad
voor de Volksgezondheid), now Council for Care (Raad voor de Zorg) and the
1 Health technology assessment is a comprehensive form of policy research that examines short- and
long-term social consequences (for example, economic, ethical, legal) of the application of health
technology [1,2]. Health technology is defined very broadly as the pharmaceuticals, devices, and
procedures offered by the health care system, and the organisational and support systems within which
health care is delivered.
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Health Council (Gezondheidsraad). All three organisations advised that HTA
should be seen as a help for decision-making [7]. One result was the establishment
of the Fund for Investigative Medicine (Fonds Ontwikkelingsgeneeskunde) in
1988. This Fund is the main HTA programme in the Netherlands (approximately
US $18 million/year), and is administered by the Health Insurance Council. At
the end of 1988 The Council for Health Research (Raad voor Gezondheidsonder-
zoek) published a document on HTA, giving guidance for institutionalisation of
HTA in the Netherlands [8]. By the 1990s HTA had become an important policy
issue and all medical faculties and university hospitals currently are involved in
HTA. The Ministry of Health, Welfare and Sports (VWS) and the Ministry of
Education, Culture and Science (OCW) fund the Investigative Medicine Program,
and sometimes fund other specific technology assessments as well. In the past the
Dutch government has not taken a leadership role in steering HTA. However, a
recent policy document ‘Medical technology assessment and efficiency in health
care’ [9] proposed a more active role for the government, focusing on promoting
greater efficiency in the health care sector by means of stimulating HTA. The
Minister states that HTA has been growing during the last years in the Nether-
lands. She proposed a comprehensive health research policy based on transparent
decision making and identification and prioritisation of health technologies [9].
Identification and prioritisation of health technologies are of main importance for
a health system. Health technologies can have desirable and undesirable effects on
health services and patients, and therefore they need to be assessed. Only a
fraction of existing health technologies has been formally evaluated, and many
more appear each year. However, resources for HTA are limited so that priorities
have to be set. A more rational process of identifying and setting priorities can
help to ensure that the maximum benefits in relation to their cost are realised for
a health system [10].
In this article the main actors involved in identification and priority setting for
HTA on a national level in the Netherlands are described. The scope, strengths
and weaknesses of the current activities are discussed, followed by recommenda-
tions for a more comprehensive approach for identification and priority setting
for HTA in the Netherlands.
2. Methods
The literature on HTA published in 1980–1998, mainly national, was thor-
oughly reviewed. Many national policy documents and other reports from the
‘grey literature’ of identification and priority setting for HTA in the Netherlands
were used.
One of the main sources used is a document on the organisation of HTA in the
Netherlands, which was published in 1996 [11]. This document describes the
situation of HTA in the Netherlands, focusing on the years 1985–1995. The aim
of the document was to contribute to a discussion of the organisation of HTA in
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the Netherlands. The National Library of Medicine’s bibliographic database (Med-
line) was searched for the years 1996–1998 as part of the literature review to
identify articles, books and ‘grey’ literature related to identification and priority
setting of health technologies in the Netherlands. In the search strategy we used the
key words: identification and/or priority setting and health technologies. National
policy reports, published in 1996–1998 were retrieved by hand searching national
(policy) journals covering health policy issues (Nederlands Tijdschrift voor Ge-
neeskunde, Medisch Contact, Tijdschrift voor Sociale Gezondheidszorg, Mediator
and Graadmeter).
The actors and their activities involved in the identification phase will be
described first, since a decision to conduct HTAs must be preceded by the
identification of health technologies or health problems that are potentially in need
of assessment. Secondly, actors and their activities involved in priority setting on a
programme level will be described. Priority setting on a programme level means
that the priorities are described in general terms, such as ‘HTA research into mental
health care facilities’. These priorities do not always relate to a specific HTA
programme. Thirdly, the actors involved in priority setting within HTA pro-
grammes, such as the Health Insurance Council and its Fund Investigative
Medicine, will be described. Within HTA programmes, priorities are set between
individual proposals for assessment (project level).
3. Results
3.1. Identification
The organisations involved in the identification of health technologies or health
problems in need of assessment are the Health Council, the Health Insurance
Council and the Council for Health Research. Since the latter two actors combine
identification and priority setting, they will be described in the paragraphs on
priority setting.
3.1.1. Health Council
The Health Council is the statutory body advising the government on the
scientific state of the art with respect to health care, public health and environmen-
tal protection in the Netherlands. Its involvement in HTA is based on this
responsibility. To carry out its task, the Council brings together groups of experts
on specific topics at the request of the government, but it can also initiate studies
on its own [11]. The Health Council identifies emerging technologies needing
assessment through a type of Delphi process. The assessments of existing technolo-
gies are derived from the ‘126’-list of the Health Insurance Council, which will be
described below. The top-five priorities of HTA described in the Annual report of
1997 and the Working programme of 1999 are listed in Table 1(A) [12]. The Health
Council is strengthening its ‘early warning’ activities. At the end of 1994 a ‘core
group’ for early identification of emerging technologies was established. At present,
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it discusses important emerging health technologies in its Annual Advisory Reports,
special case studies and in bulletins. Recently, an international working group has
been formed, as a result of a European workshop on ‘Scanning the Horizon for
Emerging Medical Technologies’ in 1997. A Health Council staff member chairs
this group, which is called EUROSCAN. The aim of this working group is to
support national agencies and HTA organisations in developing and running
systems in early identification of health technologies to provide useful information
to health planners and policy makers.
Table 1
Top 5 priorities indicated by different actors involved in identification and setting priorities for HTA
A Priorities from the Health Council, deri6ed from the ‘126’-list, as described in the Annual working
programme for 1999 [12]
1. Incontinence
2. Chronic use of benzodiazepines
3. Decubitus
4. Use of devices in physiotherapy
5. Long-term psychotherapy
B. Priorities from the Council for Health Research and Committee on Explorations, as published in a
report on exploring priorities in health research in 1996 [14]
1. Diagnosis and treatment of chronically ill: e.g. mental problems in children and adolescents;
adults and depression
2. Adequate care of diseases which occur in the elderly, impairments: endocrine aspects of ageing,
dementia and CVA
3. Stimulating autonomy and self-care: the patient as actor in health care and home care
technology
4. Primary and secondary prevention: innovative prevention, effectiveness and efficiency of
preventive technologies and implementation
5. Quality and efficiency of care: evaluation of medical practice, clinical decision making regarding
diagnostics and quality of care
C. Priorities from the Council for Health Research as described in the ad6ice on HTA, 1998 [17]
1. HTA research into the economic aspects of existing technologies (especially topics on the
‘126’-list), new technologies including medicalaids, and drugs
2. HTA research which covers not only the efficacy (and possible costs) but also other aspects,
such as regional and individual differences inthe care provided, highly complex care, the national
policy on quality of health care and the macro-economic impact of (new) healthtechnologies
and/or care technologies
3. HTA research into prevention and diagnostic procedures
4. HTA research into nursing and paramedical care facilities
5. HTA research into mental health care facilities
D. Priorities from the ‘126’-list as published by the Health Insurance Council in 1993 [18]
1. Ultrasound treatment for problems of the locomotor system
2. Treatment and cure of non-hospitalised acute psychiatric patients
3. Specialists care for chronic patients
4. Diagnosis of suspected hernia nucleus pulposa
5. Diagnostic arthroscopy of the knee compared to diagnostic MRI
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3.2. Priority setting on a programme le6el
3.2.1. Council for Health Research
The Council for Health Research (RGO) is involved in priority setting on a
programme level. This Council advises the Dutch government on policy issues
regarding health research, including HTA. The RGO monitors current research,
pointing out gaps and overlaps and provides advice on co-ordination and program-
ming of research [13]. Its main task is to indicate priorities for health research from
a societal perspective. Priorities are not chosen only because they are of scientific
interest, but because of their importance regarding public health in the future. In
1988, an advisory report on HTA was published, including a framework for setting
priorities for HTA [8]. In 1996 the Council published a report on exploring
priorities in health research, in collaboration with the Committee on Explorations
(Overlegcommissie Verkenningen, OCV) [14]. The aim of the Committee on Explo-
rations, established in 1992 by the Minister of Education and Science, is to explore
the strategic importance of scientific and technical research in the long term. The
RGO and the OCV established a working group, which consulted about 140
experts in health research and medical practice, to gain information concerning
priorities for health research during the coming years. Both societal criteria and
scientific criteria were used. The criteria for measuring the societal relevance
included: contribution to diminish the prevalence and incidence of disease; contri-
bution to diminish mortality; contribution to improving the quality of life; contri-
bution to diminish the cost of health care; and developments in the future
(demography, technological).
The scientific criteria include: availability of expertise in the Netherlands,
availability of an excellent research environment and the extent to which research
on the topic is already being performed in the Netherlands or abroad [14]. The
subjects to be prioritised were derived from the report Exploring the Future of
Public Health [15] and an RGO-advice on Prevention [16]. On the basis of a
Delphi-like prioritisation process, fields of interest were selected. The five most
important fields are listed in Table 1(B) [16]. In 1996, the Dutch Minister of Health
has asked the RGO, by means of the policy document ‘Medical technology
assessment and efficiency in health care’ to prepare a report on priority setting for
HTA, on ways in which co-ordination should be improved, and on the feasibility
and design of a national research programme aimed at improving the efficiency of
health care [9]. For this purpose the RGO organised a workshop in 1997 to identify
critical issues in setting priorities. The RGO has decided to publish its recommenda-
tions in two parts. Part I, published in 1998, deals with the gaps in HTA research
experienced by both the supply and demand side of the market for HTA. On the
basis of these findings the RGO listed a number of subjects in the field of HTA
which are nominated for further priority ranking. Table 1(C) provides an overview
of the 5 most important priorities. In the second part of the recommendations, the
RGO plans to consider in more detail the subjects proposed in Part I and criteria
for priority setting. Part II will also include an elaboration of the recommendation
to establish a committee with the task of co-ordinating HTA research, and that of
the recommendation for monitoring HTA research [17].
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3.3. Priority setting on project le6el
In the Netherlands mainly three organisations are involved in priority setting on
a project level. These organisations are: The Health Insurance Council, the Dutch
Health Research and Development Council (ZorgOnderzoek Nederland) and the
Netherlands Organisation for Scientific Research (Nederlandse Organisatie voor
Wetenschappelijk Onderzoek).
3.3.1. Health Insurance Council
The Health Insurance Council administers the Exceptional Medical Expenses Act
(Algemene Wet Bijzondere Ziektekosten) and the Health Insurance Act (Zieken-
fondswet). The Health Insurance Council informs and reports to the Crown and the
minister responsible, at their request or on its own initiative regarding issues
concerning both Acts. In addition, the Health Insurance Council funds health
research, including HTA, within the Fund Investigative Medicine. The Health
Insurance Council set priorities for HTA regarding existing provisions by a
Delphi-type process in 1993. Medical advisors of insurance companies and other
experts were asked to identify priorities among existing technologies and to
subsequently rate them on selected criteria, such as cost. One hundred and
twenty-six priorities (‘126’-list) were identified, and were presented in rank order
[18]. The following criteria were used: the degree of uncertainty concerning efficacy,
effectiveness or efficiency; frequency of use; costs; the extent to which the concerned
technology could potentially decrease morbidity or mortality and increase quality
of life; and the extent to which technology assessment results could change the rate
of use of the technology [18]. The top-five priorities, based on these criteria, are
listed in Table 1(D). This was the first attempt to rationalise priority setting for
HTA in the Netherlands. This approach was intensely debated [19–23]. Although
imperfect, this ‘126’-list was judged to be useful for follow-up activities by both the
Health Insurance Council and the Health Council. Recently, the Health Insurance
Council initiated an actualisation of the 126-list. In the beginning of 1998 the
Health Insurance Council sent a questionnaire to experts and organisations in-
volved in health care asking for identification of health technologies (in the broad
sense) which could be applied more efficient. This inventory led to a list of 194
topics. The Health Insurance Council will prioritise the topics on the basis of the
following criteria: potential change in cost on an aggregate level; potential health
gain; and number of people affected [24]. This list will be used as an input for a
top-down approach within the Fund Investigative Medicine. In the top-down
approach, which started in 1993, selected groups of researchers are invited to
submit a full research proposal focusing on a specific topic. Only those proposals
are eligible for assessment addressing the selected topic [25].
In addition, the Health Insurance Council developed a more explicit model for
priority setting within the Fund Investigative Medicine in 1998. Research proposals
focusing on new or existing health technologies can be submitted to this Fund. In
different reports the Health Insurance Council described criteria for identifying the
relevance of HTAs for policy making. These criteria are: potential health benefits;
W. Oortwijn et al. / Health Policy 47 (1999) 241–253248
potential financial benefits or costs; expectation of feasible and valid results and
possibilities for implementing them; costs of the proposed project and special
circumstances, such as anticipated rapid diffusion of health technology [26,27]. To
judge research proposals, submitted to the Fund Investigative Medicine in 1998,
on their relevance for policy making in the perspective of the goals of the Health
Insurance Council, specific information about these criteria was asked for in the
application form. Based on this information a judgement form was made for
reviewing the relevance for policy. Several methods for ranking priority setting
were studied, including ranking on the basis of absolute numbers, equal scales,
logarithmic scales, exponential scales and a subjective estimation of the reviewer.
The results of this exercise will become available in 1999.
3.3.2. Dutch Health Research and De6elopment Council
The Dutch Health Research and Development Council (ZON) was initiated in
1996 to promote the efficient allocation of government funds for applied health
research. ZON is an intermediary organisation between the Ministry of Health
and the research community. ZON is responsible for programming, priority set-
ting and the actual allocation of research funds regarding health, prevention and
care, including the organisation of care. ZON organised different types of re-
search programmes, such as Quality of Health Care, Prevention, Home Care
Technology and Efficiency in Health Care. Each programme is formulated by a
working group of experts. The working group judges all research proposals on
their relevance for the programme. The relevance is assessed by means of two
variables: the extent to which the project contributes to the aim of the programme
and the probability of implementing the results. The working group of the
programme decides whether a research proposal will be approved or not [28].
However, the methods used for setting priorities between proposals are not
explicitly described.
3.3.3. Netherlands Organisation for Scientific Research
The Netherlands Organisation for Scientific Research (NWO) is a statutory
organisation with the main purpose of improving the quality of scientific research
in the Netherlands [29]. In 1989, health-related research was formally recognised
as one part of NWO and a separate board was installed, the Board for Medical
Science (Gebiedsbestuur Medische Wetenschappen, GB-MW). The GB-MW has
not only emphasised scientific quality, but has attempted to improve societal-rele-
vant research within different programmes. However, criteria and methods used
for priority setting are not explicit nor are they transparent. NWO also plays an
important role in the Fund Investigative Medicine. A special NWO committee
evaluates the research proposals to that program for scientific quality and feasibil-
ity. Without a positive opinion from NWO, proposals within the Fund Investiga-
tive Medicine are unlikely to be funded [30].
The actors involved in identification and priority setting for HTA in the
Netherlands are not closely linked (Fig. 1) and they indicate different priorities
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Fig. 1. Relation between actors involved in identification and priority setting for health technology
assessment in the Netherlands.
for HTA for different purposes (Table 1). The organisations do collaborate within
some HTA-programmes, such as the Health Insurance Council and the Netherlands
Organisation for Scientific Research within the Fund Investigative Medicine, and
the Health Council and the Health Insurance Council with regard to the ‘126’-list.
However, all actors mentioned do not work together towards a common goal.
Without such collaboration, the desire of the Ministry of Health to have a
successful national program for efficiency in health care, will not be realised [9].
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4. Discussion
The three most important players in the field of identifying and priority setting
for HTA in the Netherlands, in our opinion, are the Health Council, the Council
for Health Research and the Health Insurance Council. Unfortunately, these
organisations take different approaches. This is not remarkable, since the overall
approach relates to the nature of the programme for which priorities are being
identified, and the division of responsibilities [10]. However, the three organisations
have not yet described explicitly the ways in which priorities for HTA are to be
identified, who is responsible for particular elements in the priority setting process,
and who will be involved in the process. For example, priority-setting exercises have
been performed separately by the Health Insurance Council and the Health Council
regarding the ‘126’-list with different methods and different results. It can be
concluded that the methods used are typically not very transparent, and thus
explicit criteria are seldomly used. The probable reason for this is that methods for
setting priorities on the basis of societal criteria are not well developed. Another
reason is that crucial elements in priority setting for HTA can not be based on
sound (scientific) evidence. The initiative of the Health Insurance Council in 1998
to develop a more explicit model for priority setting for the Fund Investigative
Medicine is a step forward in making the process more evidence based and more
transparent.
Input for the identification and priority setting process can be obtained from
organisations who provide the actors on the national level with useful information
for policy making, such as the National Institute for Health and Environmental
Hygiene (Rijksinstituut voor de Volksgezondheid en Milieuhygiëne, RIVM). The
RIVM is involved in basic data collection relating to the health of the Dutch
population and the functioning of the health care system. In 1993, RIVM published
a major report, ‘Exploring the future of public health’ (Volksgezondheid Toekomst
Verkenningen, VTV) that presented a great deal of information on the health of the
Dutch population [15]. This information was helpful for identifying areas for
priority setting for HTA [14]. In 1997 an extended update of the report was
published. The reports are used for evaluation of recent health policy, as well as for
formulating future health policy [31]. Not only national organisations can be of
relevance for an input in the identification and priority setting process. Lessons can
also be learned from international collaboration, such as the EUR-ASSESS project.
The aim of EUR-ASSESS was to stimulate and co-ordinate developments in HTA
in Europe and to improve decision-making concerning adoption and use of health
technology. One of the formal objectives of the project was to improving ap-
proaches to identifying priorities for assessments and to review and advise on
methods for priority setting for HTA, which was studied by the Priority Setting
Subgroup [10].
To improve the identification and priority setting process for HTA in the
Netherlands, it seems to be essential to develop a more co-ordinated effort. The
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different actors need to become a team, sharing experiences with their priority
setting models and deciding about responsibilities. Lessons can be learned from
countries performing practical priority setting processes, such as the United
Kingdom and the Basque country of Spain [10]. It should be clear that the
general approach for priority setting should reflect the goals of the programme,
the resources available and the working methods of those involved. This means
that the perspectives of both decision-makers and researchers need to be consid-
ered [10]. In the end of 1997 the first steps towards a more co-ordinating effort
regarding the ‘126’-list have been mounted by Health Insurance Council and the
Health Council, as was recommended by the policy document of the Minister of
Health [9]. In a policy letter of the Minister of Health, also representing the
Minister of Education, Culture and Science, to the Permanent Commission for
Health, Welfare and Sports, the RGO was asked for advice on efficiency in
health care. The Minister specifically asked the RGO for advice on a permanent
co-ordinating body for HTA [32]. In its advice letter, the RGO recommends a
national ‘platform’ for HTA [32]. Members of the platform should include:
members of the Health Council, the Health Insurance Council, the Board for
Medical Science of the Netherlands Organisation for Scientific Research, the
Health Research and Development Council, the Association of University Hospi-
tals (Vereniging van Academische Ziekenhuizen, VAZ) and the Council for
Health Research, as well as representatives of patient/consumer groups, profes-
sional groups, medical insurance organisations and the industry (pharmaceutical
companies and medical device organisations). The main task of the platform,
according to the RGO, is to develop information about existing studies in the
Netherlands, and the need for more HTAs in other subjects. It is the responsibil-
ity of the platform, according to the RGO, to provide the RGO every 2 years
with a report on HTA activities on a national and international level, and on
the needs for new HTA activities. This report should serve as an input for the
advice of the RGO to the Minister on the long-term programme of HTA in the
Netherlands [33]. It is our belief that if those responsible for different HTA
programs share information in and about the priority setting process, possibili-
ties can be identified and discussed for joint and sometimes expensive assess-
ments. This will imply that value for money from investment in HTA could be
increased at both the programme level and overall.
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